Clinical Research Operations Manager
Planned Parenthood Southeastern Pennsylvania is the local affiliate of the country’s leading sexual and reproductive health care advocate and provider. Planned Parenthood Southeastern Pennsylvania (PPSP) operates 10 health centers throughout Chester, Delaware, Montgomery, and Philadelphia counties. Nationwide, Planned Parenthood affiliates operate more than 600 health centers, providing medical services and sexuality education for millions of individuals (adults and teens) each year. We also work with allies worldwide to ensure that all people have the right and the means to meet their sexual and reproductive health care needs.
If you are passionate about reproductive health and the opportunity to contribute in a mission-drive environment, consider joining PPSP as Clinical Research Operations Manager. This is a benefits-eligible, full-time, 35 hour/week position responsible to oversee the day-to-day operations of all clinical research acti
Wesana Health Closes $4 Million Convertible Note Round
News provided by
Share this article
New additions to senior management and leadership teams
CHICAGO, Jan. 21, 2021 /PRNewswire/ Wesana Health, an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, has announced the close of a $4 million convertible note financing round. The company also announced new additions to its senior leadership team.
Wesana Health Raises Funds to Enter the Psychedelics Space
The $4 million round, led by The Conscious Fund and Ambria Capital, LLC, provides funding to support the Company s entry into the emerging psychedelics space. The proceeds will allow Wesana to begin preclinical and clinical work on the use of psychedelic-assisted therapy to treat traumatic brain injury (TBI) as well as regulatory applications including Investigational New Drug (IND) filings with the Food and Drug Administration (FDA),
Share this article
Share this article
WEST HOLLYWOOD, Calif., Jan. 20, 2021 /PRNewswire/ ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM patients.
Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered RUX, LEN and methylprednisolone (MP) demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids (Berenson
et al.,
Clin Cancer Res. 2020). The clinical and overall response rates were 46% and 28%, respectively, and all 12 responding patients were refractory to LEN.